GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

RaQualia Pharma 4579.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

650

+13.44%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥3.98bn

FY2016FY2025

Net income

¥273.1m

FY2016FY2025

Free cash flow

−¥424.0m

FY2016FY2025

Shareholders' equity

¥6.90bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue¥3.98bn¥3.11bn¥1.90bn¥2.92bn¥2.78bn¥1.11bn¥1.70bn¥744.5m¥1.42bn¥705.2m
Gross profit¥3.27bn¥2.48bn¥1.66bn¥2.69bn¥2.46bn¥969.3m¥1.44bn¥655.1m¥1.27bn¥587.6m
Research and development¥1.60bn¥1.70bn¥1.37bn¥1.25bn¥1.13bn¥932.5m¥864.3m¥1.07bn¥848.5m¥796.2m
Operating income¥483.7m−¥322.0m−¥337.4m¥866.2m¥707.9m−¥486.1m−¥25.8m−¥1.08bn−¥150.4m−¥759.9m
Net income¥273.1m−¥495.0m−¥323.7m¥723.4m¥755.8m−¥607.0m¥5.3m−¥1.10bn−¥58.1m−¥728.1m
Diluted earnings per share11.56-22.85-14.9734.4536.05-28.970.26-54.18-2.86-38.18

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets¥10.51bn¥9.66bn¥6.93bn¥6.26bn¥5.23bn¥4.25bn¥4.84bn¥4.05bn¥5.06bn¥4.02bn
Cash and short-term investments¥3.24bn¥3.34bn¥3.76bn¥3.93bn¥2.66bn¥2.11bn¥2.20bn¥1.84bn¥2.60bn¥1.44bn
Total liabilities¥3.62bn¥4.08bn¥809.8m¥760.7m¥446.2m¥240.1m¥215.9m¥195.2m¥176.2m¥231.3m
Debt¥2.90bn¥3.45bn¥432.0m¥222.3m¥39.1m¥45.5m¥2.4m¥3.1m——
Shareholders' equity¥6.90bn¥5.57bn¥6.12bn¥5.50bn¥4.79bn¥4.01bn¥4.62bn¥3.86bn¥4.89bn¥3.79bn
Shares outstanding24m22m22m21m21m21m21m20m20m19m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−¥356.6m¥180.9m−¥718.6m¥1.48bn¥366.0m−¥289.2m−¥530.8m−¥404.0m−¥307.4m−¥680.9m
Capital spending−¥67.4m−¥96.7m−¥222.2m−¥31.9m−¥105.4m−¥156.3m−¥94.4m−¥221.1m−¥88.4m−¥37.2m
Free cash flow−¥424.0m¥84.2m−¥940.8m¥1.45bn¥260.6m−¥445.6m−¥625.2m−¥625.1m−¥395.9m−¥718.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥653.6m¥802.0m¥1.67bn¥775.1m¥570.6m¥965.4m¥738.1m¥958.4m
Gross profit¥494.6m¥551.3m¥1.50bn¥548.5m¥335.3m¥672.6m¥509.2m¥788.5m
Operating income−¥178.3m−¥160.2m¥828.5m−¥154.6m−¥283.3m¥93.1m−¥186.2m¥127.0m
Net income−¥240.9m−¥225.7m¥842.1m−¥214.2m−¥349.5m−¥5.2m−¥155.1m−¥16.0m
Diluted earnings per share-9.26-8.6735.65-9.07-14.80-0.22-7.16-0.74
Cash from operations¥355.0m¥256.0m−¥182.0m¥70.0m¥57.0m−¥301.0m−¥48.0m¥358.0m
Capital spending−¥12.0m−¥10.0m−¥3.0m−¥14.0m−¥37.0m−¥11.0m—−¥63.0m
Free cash flow¥343.0m¥246.0m−¥185.0m¥56.0m¥20.0m−¥312.0m—¥295.0m
Total assets¥11.01bn¥11.39bn¥10.51bn¥9.52bn¥9.94bn¥9.51bn¥9.66bn¥9.75bn
Cash and short-term investments¥4.70bn¥4.49bn¥3.24bn¥3.54bn¥3.62bn¥2.76bn¥3.34bn¥3.20bn
Debt¥2.49bn¥598.3m¥2.73bn¥589.1m¥2.98bn¥590.3m¥582.3m¥582.6m
Shareholders' equity¥7.83bn¥8.09bn¥6.90bn¥6.04bn¥6.29bn¥5.50bn¥5.57bn¥5.63bn

Financial ratios

Data as of 25 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin82.1%79.9%87.1%92.1%88.4%87.5%
Operating margin12.2%-10.4%-17.7%29.7%25.5%-43.9%
Net margin6.9%-15.9%-17.0%24.8%27.2%-54.8%
Return on equity4.0%-8.9%-5.3%13.2%15.8%-15.1%
Return on assets2.6%-5.1%-4.7%11.6%14.4%-14.3%
Free cash flow yield-2.0%2.1%-3.8%11.9%3.7%-1.0%
Revenue growth28.1%63.5%-34.8%5.1%150.7%-35.0%
Earnings growth-155.2%52.9%-144.7%-4.3%-224.5%-11460.4%
Current ratio4.46x3.82x12.73x9.77x10.00x15.18x
Debt to equity0.40x0.58x0.03x0.01x0.00x0.00x
Equity ratio65.6%57.7%88.3%87.8%91.5%94.4%
Interest coverage8.19x-1.75x-50.50x144.49x486.84x-1114.86x
R&D as a share of sales40.2%54.8%72.2%42.8%40.6%84.2%
Buybacks as a share of market value-9.0%-0.2%-3.0%-0.2%-0.1%-0.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue10.9%29.2%39.2%
Operating income-17.7%——
Net income-27.7%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin81.1%84.8%85.6%85.6%
Operating margin2.3%5.8%5.8%-14.5%
Net margin-3.1%1.5%2.1%-16.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings87.4-16.8-46.035.832.6-34.5—-19.9-822.0-10.4
Price to sales6.02.77.88.98.918.916.529.533.710.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.